RenovoRx, Inc. (RNXT) - Dilution Analysis

10-Q filing | 45.1M shares outstanding

S-3 filing: This prospectus relates to the resale by the selling stockholders named herein, including their transferees, assigns, pledgees or donees, or their respective successors, of an aggregate of up to 8,438,790 shares of our common stock, 2,200,000 shares of our common stock issuable upon exercise of pre-funded warrants and 5,319,392 shares of our common stock issuable upon the exercise of revenue milestone warrants.

10-K filing | 45.1M shares outstanding

8-K filing: RenovoRx, Inc. closed a private placement offering on March 20, 2026, selling 8,438,790 shares of common stock, pre-funded warrants for 2,200,000 shares, and revenue milestone warrants for 5,319,392 shares to accredited investors for gross proceeds of approximately $10 million. ($10.0M proceeds)

S-3 filing: RenovoRx, Inc. is filing a shelf registration statement on Form S-3 to offer and sell, either individually or in combination, various securities including common stock, preferred stock, purchase contracts, warrants, subscription rights, depositary shares, and debt securities, for total gross proceeds of up to $50,000,000.

10-Q filing | 36.6M shares outstanding

10-Q filing | 36.6M shares outstanding

10-K filing | 36.5M shares outstanding

8-K filing: RenovoRx, Inc. entered into an underwriting agreement to sell 11,523,810 shares of common stock at $1.05 per share in a firm commitment underwritten public offering, with expected net proceeds of approximately $10.9 million, and will issue warrants to the underwriter to purchase 576,191 shares of common stock at an exercise price of $1.21 per share. ($12.1M proceeds)

10-Q filing | 24.9M shares outstanding

10-Q filing | 24.0M shares outstanding

10-Q filing | 24.0M shares outstanding

S-3 filing: This S-3 filing is for the resale of common stock, pre-funded warrants, Series A warrants, Series B warrants and placement agent warrants held by selling stockholders.

S-3 filing: This is an S-3 filing for the resale of common stock, warrant shares and PA warrant shares by selling stockholders.

8-K filing: RenovoRx, Inc. closed a private placement offering on April 11, 2024, issuing 6,960,864 shares of common stock, pre-funded warrants for 951,500 shares, Series A warrants for 7,912,364 shares, Series B warrants for 3,956,182 shares, and Placement Agent warrants for 701,243 shares, raising gross proceeds of approximately $11.1 million. ($11.1M proceeds)

8-K filing: RenovoRx, Inc. entered into subscription agreements for a private placement offering to sell 7,912,364 shares of common stock, Series A Warrants to purchase up to 7,912,364 shares, and Series B Warrants to purchase up to 3,956,182 shares at a price of $1.4075 per share and related warrants. ($11.14M proceeds)

10-K filing | 16.9M shares outstanding

8-K filing: RenovoRX, Inc. closed a private placement offering on January 26, 2024, selling 6,133,414 shares of common stock and warrants for gross proceeds of $6,111,695. ($6.11M proceeds)

10-Q filing | 10.7M shares outstanding

10-Q filing | 10.7M shares outstanding

10-Q filing | 10.1M shares outstanding

S-3 filing: The filing is for the resale of up to 1,947,040 shares of common stock issuable upon the exercise of warrants by the selling stockholder, Armistice Capital Master Fund Ltd. The company will not receive any proceeds from the sale of common stock, except for funds received from the exercise of warrants.

8-K filing: RenovoRx, Inc. entered into a securities purchase agreement to sell 1,000,000 shares of common stock and pre-funded warrants to purchase up to 557,632 shares of common stock in a registered direct offering, and also agreed to issue unregistered warrants to purchase up to 1,947,040 shares of common stock in a concurrent private placement, with the closing of the offerings taking place on April 3, 2023, and aggregate proceeds of approximately $5.00 million.

10-K filing | 9.1M shares outstanding

10-Q filing | 9.1M shares outstanding

S-3 filing: This is an S-3 filing to register an offering of common stock, preferred stock, debt securities and purchase contracts with an aggregate offering price not to exceed $50,000,000.

S-1 filing: The company filed an S-1 relating to its initial public offering of units, with each unit consisting of one share of common stock and one warrant. The underwriters also had an over-allotment option to purchase additional shares or warrants. Underwriters were issued a warrant to purchase common stock.

10-Q filing | 9.1M shares outstanding

10-Q filing | 9.0M shares outstanding

10-K filing | 9.0M shares outstanding

10-Q filing | 8.9M shares outstanding

S-1/A filing: RenovoRx, Inc. is offering 1,800,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock and 1,800,000 pre-funded units, each consisting of a pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock in its initial public offering.

S-1/A filing: Initial public offering of up to 1,850,000 Units, each consisting of one share of common stock and three-quarter warrant to purchase one share of common stock, and up to 1,850,000 Pre-funded Units, each consisting of a pre-funded warrant to purchase one share of common stock and three-quarter warrant to purchase one share of common stock.

S-1/A filing: Initial public offering of up to 1,850,000 units, each consisting of one share of common stock and three-quarter warrant to purchase one share of common stock, and up to 1,850,000 pre-funded units, each consisting of a pre-funded warrant to purchase one share of common stock and three-quarter warrant to purchase one share of common stock.

S-1/A filing: RenovoRx, Inc. is offering 1,550,000 units of securities in an initial public offering, with an anticipated initial public offering price between $12.00 and $14.00 per unit.

S-1 filing: RenovoRx, Inc. is filing an S-1 form for an initial public offering of units, with each unit consisting of one share of common stock and one warrant to purchase one share of common stock, with Roth Capital Partners, LLC as the underwriter.